Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis Nes-Ziona, Israel

Enlivex Announces Completion of Enrollment

In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage

reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its

randomized, controlled, blinded Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis. Overall,

133 patients were randomized and treated in the Phase II stage.

Oren Hershkovitz, Ph.D, CEO of Enlivex, commented,

"We are pleased to have completed the recruitment of patients in the Phase II stage of this trial, which follows the recently announced

promising initial efficacy data from the Phase I stage. We therefore reiterate our timeline objective to obtain 3-month topline data by

August 2025. We believe Allocetra has the potential to transform the way osteoarthritis patients are being treated today, and we

are eager to receive the topline data of the trial."

ABOUT THE PHASE I/II CLINICAL TRIAL IN MODERATE TO SEVERE KNEE OSTEOARTHRITIS

The multi-center Phase I/II clinical trial

consists of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and

tolerability of Allocetra injections to the target knee, in order to identify the dose and injection regimen for the

subsequent Phase II stage. Recently the Company announced positive interim 3-month and 6-month

efficacy data for the first 12 patients treated in this Phase I stage, demonstrating marked statistically significant improvements

in all key efficacy endpoints and no safety issues. The Phase II stage, which completed its patient enrollment, is a

double-blind, randomized, placebo-controlled multi-center trial. In addition to evaluating safety, the study design includes an

interim statistical evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of

the enrollment of up to 50 patients in addition to the originally targeted randomized sample size, and its marginal impact on the

p-value of the statistical estimation of the total group and/or specific sub-group. In addition, the study incorporates an

independent data safety and monitoring board (DSMB) that reviews the safety data at predefined time points. The trial's

key efficacy end points will evaluate joint-pain and joint-function in comparison to placebo at three months, six months and post

treatment, including 12 month follow up. The Company expects a topline data readout from the Phase II stage, including full 3-month

endpoints, by August 2025.

ABOUT KNEE OSTEOARTHRITIS

Osteoarthritis is by far the most common form

of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL

injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic

knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their

lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement.

The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis

is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines

Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint.

Enlivex is a clinical stage macrophage reprogramming

immunotherapy company developing Allocetra , a universal, off-the-shelf cell therapy designed to reprogram macrophages into their

homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution

of life-threatening and life debilitating conditions. For more information, visit https://enlivex.com/.

Safe Harbor Statement: This press release contains

forward-looking statements, which may be identified by words such as "expects," "plans," "projects,"

"will," "may," "anticipates," "believes," "should," "would," "could,"

"intends," "estimates," "suggests," "has the potential to" and other words of similar

meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results

of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs.

All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of

1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business

and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that

the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support

the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue

to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth

in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results

of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed,

later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number

of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision

making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and

other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should

consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities

and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange

Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we

do not undertake any obligation to update forward-looking statements, except as required under applicable law.

Shachar Shlosberger, CFO

Enlivex Therapeutics, Ltd.

INVESTOR RELATIONS CONTACT

RedChip Companies Inc.